Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorambucil and Subcutaneous Rituximab in MALT Lymphoma
NCT01808599Phase 2Active, not recruiting
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Dec 2013
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of rituximab in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, sponsored by International Extranodal Lymphoma Study Group. Started Dec 2013; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Beyond the preview
Go deeper on NCT01808599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01808599.